Modified-Release 5-ASA Formulation for Distal Gut Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory bowel disease (IBD) using 5-ASA face challenges such as side effects, high doses, and inefficient delivery to the distal gut due to instability in gastric fluids and extensive absorption in the small intestine, leading to systemic exposure and reduced efficacy.
Innovation Solution
Development of modified-release formulations of 4-ASA and 5-ASA that utilize aminosalicylate pro-drugs like sulfasalazine, olsalazine, and balsalazide, combined with water-soluble and water-insoluble polymers, to achieve pH-independent drug release and maximize metabolism in the distal gut, minimizing systemic absorption and enhancing local action.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If 5-ASA is administered orally to treat IBD, then the drug can reach the distal gut, but extensive absorption in the small intestine reduces availability at distal sites and causes systemic side effects
Solution Approach 1:
The patent divides the drug delivery system into multiple segments: an enteric-coated outer layer that protects the drug during gastric transit, and an inner matrix formulation that controls release in the distal gut. This segmentation prevents premature absorption in the small intestine while ensuring targeted delivery to the colon, thereby reducing systemic exposure and side effects.
Solution Approach 2:
The patent uses an enteric coating as an intermediary barrier that prevents 5-ASA from interacting with the small intestine environment. This coating acts as a mediator that allows the drug to pass through the upper GI tract unchanged and only releases the active compound in the distal gut where it is needed, minimizing systemic absorption.
2Reliability
If high doses of 5-ASA are administered to achieve therapeutic effect, then efficacy improves, but side effects increase and patient compliance decreases
Solution Approach 1:
The patent applies local quality by concentrating the drug release specifically at the site of action (distal gut) rather than distributing it systemically. The enteric-coated matrix formulation ensures that 5-ASA is released only in the colon where IBD pathology is present, maximizing local therapeutic effect while minimizing systemic exposure and associated side effects.
Solution Approach 2:
The patent changes the release parameters of 5-ASA by using an enteric-coated matrix system that controls the timing and location of drug release. This transforms the delivery profile from immediate systemic release to delayed localized release, improving the therapeutic index by enhancing efficacy at the target site while reducing systemic side effects.
3Ease of manufacture
If conventional formulations are used, then manufacturing is simple, but drug stability in gastric fluids is poor and delivery to distal gut is inefficient
Solution Approach 1:
The patent employs a composite formulation consisting of an enteric coating layer combined with a matrix core containing 5-ASA and pH-independent release agents. This composite structure provides both gastric protection and controlled release in the distal gut, overcoming the limitations of conventional single-component formulations while maintaining manufacturability through established coating and compression techniques.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations provide effective concentrations of aminosalicylates to the distal gut with reduced systemic exposure, improving therapeutic efficacy and minimizing side effects by controlling the release and metabolism of the active compounds.
Implementation Method 1
The invention comprises a polymeric matrix modified-release formulation of 5-ASA... exhibiting a modified-release profile that is independent of surrounding pH
Implementation Method 2
The invention comprises a polymeric matrix modified-release formulation of 5-ASA... exhibiting a modified-release profile that is independent of surrounding pH
Implementation Method 3
SASP is broken down in the lower gut by colonic bacteria to yield sulfapyridine ('SP') and 5-ASA
Implementation Method 4
the compound is unstable in gastric fluids... Ideally, the compound should reach the distal gut (ileum and/or colon) in unchanged form
Data Source
AI summary
Methods and formulations for treating inflammatory bowel disease are disclosed. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of 4-aminosalicylic acid and/or 5-aminosalicylic acid, and pharmaceutically acceptable salts and pro-drugs thereof, to affected areas of the intestine, i.e., distal gut. The methods and formulations comprise modified-release elements, providing for drug delivery to the affected or desired area. Diseases and conditions treatable with the present invention include Crohn's disease and ulcerative colitis.